These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer]. Kubáčková K Klin Onkol; 2015; 28 Suppl 4():4S69-72. PubMed ID: 26647892 [TBL] [Abstract][Full Text] [Related]
24. Concerns about Provenge simmer as CMS ponders coverage. Goozner M J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996 [No Abstract] [Full Text] [Related]
25. Prostate cancer immunology - an update for Urologists. Rajarubendra N; Lawrentschuk N; Bolton DM; Klotz L; Davis ID BJU Int; 2011 Apr; 107(7):1046-51. PubMed ID: 21070575 [TBL] [Abstract][Full Text] [Related]
26. David Urdal. Interview with Asher Mullard. Nat Rev Drug Discov; 2011 Oct; 10(11):806-7. PubMed ID: 22037031 [No Abstract] [Full Text] [Related]
27. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Sims RB Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856 [TBL] [Abstract][Full Text] [Related]
28. Prostate cancer vaccines. Michael A; Relph K; Annels N; Pandha H Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665 [TBL] [Abstract][Full Text] [Related]
29. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Garcia JA; Dreicer R Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467 [TBL] [Abstract][Full Text] [Related]
31. Dendritic cells and T cells in immunotherapy. O'Neill DW J Drugs Dermatol; 2010 Nov; 9(11):1383-92. PubMed ID: 21061761 [TBL] [Abstract][Full Text] [Related]
32. Therapy: An immune one-two punch. Bourzac K Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788 [No Abstract] [Full Text] [Related]
33. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. Di Lorenzo G; Ferro M; Buonerba C BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289 [TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy: an emerging strategies against prostate castration resistant cancer]. Mansi L; Thiery-Vuillemin A; Kalbacher E; Nguyen T; Maurina T; Nallet J; Kim S; Borg C; Kleinclauss F; Pivot X; Adotevi O Bull Cancer; 2012 Jul; 99 Suppl 1():S57-65. PubMed ID: 22516539 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Lü C; Williams AK; Chalasani V; Martínez CH; Chin J Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858 [TBL] [Abstract][Full Text] [Related]